Management of type 1 diabetes: ADA/EASD consensus report
Anne Peters talks about the goals of the ADA/EASD type 1 diabetes management consensus report, the issues to urgently address, and the joys of being part of a trans-Atlantic collaboration (9:53). 0:00 – The goals of the report0:53 – The importance of psychosocial care3:35 – Are providers ready for routine use of technology?4:30 – Type […]
TriMaster supports precision medicine strategy for type 2 diabetes treatment intensification
Author: Claire Barnard medwireNews: Findings from the TriMaster trial suggest that stratification of people with type 2 diabetes based on clinical features may help to guide the choice of second- or third-line drug for those who require treatment intensification after metformin. “This is the first trial to directly test and prove a stratified approach in […]
FIGARO: Where will finerenone fit into diabetic kidney disease treatment?
David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors (7:22).
Risankizumab for PsA: How will the KEEPsAKE 1 and 2 findings impact clinical practice?
Speaker: Laura Coates Laura Coates comments on the results of the KEEPsAKE 1 and 2 studies, and explores where risankizumab may fit in the treatment landscape for psoriatic arthritis (5.10) https://www.youtube.com/embed/x06FLukJIjY?modestbranding=1&rel=0 Transcript So the KEEPsAKE 1 and 2 trials have looked at the efficacy and safety of risankizumab in patients with active psoriatic arthritis. And […]
ASCO 2021 Lung cancer: Clinical insights into key research
Gilberto Lopes shares his lung cancer highlights from the 2021 ASCO Annual Meeting, including the IMpower010 trial, the MYLUNG study of real-world molecular testing, and updates on the CodeBreaK 100 and CHRYSALIS studies (8:06). 00:00 – Introduction00:30 – MYLUNG study02:44 – CodeBreaK 100 trial03:52 – CHRYSALIS trial04:48 – IMpower010 trial Read transcript Hello. Thank you […]
‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA
Author: Claire Barnard medwireNews: “The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether Janus kinase (JAK) inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis (RA). Introducing the topic, Elizabeth Wahl, from the University of Washington in Seattle, USA, said that […]
UEGW 2020 | Corticosteroids but not TNF-inhibitors increase severe COVID-19 outcomes risk
Ryan Ungaro reports results from the updated SECURE-IBD registry looking at the impact patient characteristics and immunosuppressants have on COVID-19 outcomes in patients with IBD (5:45).
UEGW 2020 | Treat-to-target aids ustekinumab dosing in patients with Crohn’s disease
Silvio Danese discusses the STARDUST trial looking at the benefits of a treat-to-target strategy for optimising ustekinumab treatment in Crohn’s disease based on endoscopic and clinical outcomes (3:28).
UEGW 2020 | Ozanimod maintains remission in patients with ulcerative colitis
Silvio Danese outlines the 52-week TRUE NORTH study findings showing the benefits of ozanimod in patients with moderate-to-severe ulcerative colitis (4:11).
UEGW 2020 | Ultraproactive therapeutic drug monitoring does not outperform reactive in IBD
Peter Bossuyt discusses his pragmatic trial looking at the potential of ultraproactive therapeutic drug monitoring to improve infliximab dosing in patients with inflammatory bowel disease (5:38).
